Vosoritide is an innovative drug developed by BioMarin Pharmaceutical Inc., primarily used for the treatment of children aged 5 years and older with achondroplasia who have open epiphyses (growth plates).
VOXZOGO(Vosoritide):Clinical Uses, Recommended Dosage, Treatment Effect
As a C-type natriuretic peptide (CNP) analog, vosoritide downregulates the fibroblast growth factor receptor 3 (FGFR3) signaling, promotes endochondral bone formation, thereby directly targeting the intrinsic pathophysiological mechanisms of achondroplasia for treatment.
1. Indications
Vosoritide can promote linear growth in children with achondroplasia and open epiphyses.
2. Recommended Dosage
Recommended Dosage and Administration Methods.
(1) General Recommended Dosage and Usage
The recommended dosage of vosoritide is based on the patient's actual body weight.
Vosoritide is administered by subcutaneous injection once daily. If possible, inject vosoritide at approximately the same time each day. The dosage (injection volume) of vosoritide depends on the patient's actual body weight and the concentration of reconstituted vosoritide (0.8mg/mL or 2mg/mL). Vosoritide must be reconstituted before use.
(2) Missed Dose
If a dose of vosoritide is missed, it can be administered within 12 hours of the scheduled administration time. If more than 12 hours have passed, the missed dose should be skipped, and the next daily dose should be administered according to the usual dosage schedule.
3. Target Population
Children. Lactating women and patients with renal insufficiency should use it under the guidance of a doctor.
4. Contraindications
The contraindications of vosoritide are not clearly specified in the instruction manual.
5. Side Effects
The most common adverse reactions (>10%) are injection site erythema, injection site swelling, rash, vomiting, injection site urticaria, arthralgia, hypotension, and gastroenteritis.
6. Precautions
Risk of Hypotension
Transient decreases in blood pressure were observed in clinical studies of vosoritide. Subjects with significant cardiac or vascular diseases and patients taking antihypertensive drugs were excluded from vosoritide clinical trials. To reduce the risk of blood pressure decrease and related symptoms (dizziness, fatigue, and/or nausea), instruct patients to maintain adequate fluid intake and sufficient food consumption before taking vosoritide.
7. Drug Interactions
The drug interactions of vosoritide are not clearly specified in the instruction manual.
8. Storage Conditions
Vosoritide for injection is a white or yellow lyophilized powder.
Refrigerate vosoritide vials and pre-filled diluent syringes at 2°C to 8°C; do not freeze.
Vosoritide can be stored at room temperature (20°C to 25°C); it is allowed to be transported at 15°C to 30°C for 90 days. Once stored at room temperature, do not return vosoritide to the refrigerator.
After reconstitution, vosoritide can be stored in the vial at room temperature (20°C to 25°C) for a maximum of 3 hours.
Clearly record the start date of room temperature storage on the unopened product carton. Do not use beyond the expiration date on the label. It should be kept in the original packaging to protect from light.
